Koepsell Scott A, Winkler Anne M, Roback John D
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.
Instrumentation Laboratory, Bedford, MA.
Transfus Med Rev. 2017 Jul;31(3):149-153. doi: 10.1016/j.tmrv.2016.11.002. Epub 2016 Nov 16.
The Ebola outbreak that began in 2013 infected and killed record numbers of individuals and created unprecedented challenges, including containment and treatment of the virus in resource-strained West Africa as well as the repatriation and treatment for patients in the United States and Europe. Valuable lessons were learned, especially the important role that the laboratory and transfusion service plays in the treatment for patients with Ebola virus disease (EVD) by providing data for supportive care and fluid resuscitation as well as the generation of investigational therapies such as convalescent plasma (CP). To provide treatment support, laboratories had to evaluate and update procedures to ensure the safety of laboratory personnel. Because there is no licensed EVD-specific treatment, CP was used in more than 99 patients with only 1 possible severe adverse event reported. However, given the biologic variability inherent in CP as well as the small number of patient treated in a nonrandomized fashion, the efficacy of CP in the treatment of EVD remains unknown.
始于2013年的埃博拉疫情感染并导致创纪录数量的人死亡，带来了前所未有的挑战，包括在资源匮乏的西非控制和治疗该病毒，以及在美国和欧洲对患者进行遣返和治疗。人们吸取了宝贵的经验教训，尤其是实验室和输血服务在埃博拉病毒病（EVD）患者治疗中发挥的重要作用，即通过提供支持性护理和液体复苏数据以及生成诸如恢复期血浆（CP）等研究性疗法。为了提供治疗支持，实验室必须评估和更新程序以确保实验室人员的安全。由于没有针对EVD的许可治疗方法，超过99名患者使用了CP，仅报告了1例可能的严重不良事件。然而，鉴于CP固有的生物学变异性以及以非随机方式治疗的患者数量较少，CP治疗EVD的疗效仍然未知。
